Why the study?
Does dabigatran reduce clinically significant deep vein thrombosis compared to rivaroxaban and apixaban in patients after large joint arthroplasty?
Cohort (n=10,241)
Yes
Does dabigatran reduce clinically significant deep vein thrombosis compared to rivaroxaban and apixaban in patients after large joint arthroplasty?
Absolute Event Rate: 9% vs 12.2%
p-value: p=<0.05
Dabigatran may offer a better efficacy and safety profile regarding deep vein thrombosis and postoperative hematomas compared to rivaroxaban and apixaban following large joint arthroplasty.
No takes yet. Share an insight, caveat, or question.
Фирсов et al. (2015) conducted a cohort in Total knee or hip arthroplasty (n=10,241). Dabigatran vs. Rivaroxaban or Apixaban was evaluated on Clinically significant deep vein thrombosis after total knee arthroplasty (p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: